0001209191-23-014787.txt : 20230302 0001209191-23-014787.hdr.sgml : 20230302 20230302170038 ACCESSION NUMBER: 0001209191-23-014787 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230228 FILED AS OF DATE: 20230302 DATE AS OF CHANGE: 20230302 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Oxtoby Andrew CENTRAL INDEX KEY: 0001765473 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37345 FILM NUMBER: 23700068 MAIL ADDRESS: STREET 1: 8000 MARINA BOULEVARD STREET 2: SUITE 300 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CHINOOK THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001435049 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-485-7051 MAIL ADDRESS: STREET 1: 400 FAIRVIEW AVENUE NORTH, SUITE 900 CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH, INC. DATE OF NAME CHANGE: 20111107 FORMER COMPANY: FORMER CONFORMED NAME: ADURO BIOTECH DATE OF NAME CHANGE: 20080514 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-28 0 0001435049 CHINOOK THERAPEUTICS, INC. KDNY 0001765473 Oxtoby Andrew C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR SEATTLE WA 98109 0 1 0 0 Chief Commercial Officer Stock Option (right to buy) 21.82 2023-02-28 4 A 0 160000 0.00 A 2033-02-27 Common Stock 160000 160000 D Restricted Stock (RSU)(Common Stock) 2023-02-28 4 A 0 40000 0.00 A Common Stock 40000 40000 D The stock option vests as to 25% of the total shares on February 28, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on February 28, 2024, until fully vested subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Kirk Schumacher, Attorney-in-Fact 2023-03-02